Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 30, 2015 3:35 AM ET

Pharmaceuticals

Company Overview of INO Therapeutics LLC

Company Overview

INO Therapeutics LLC manufactures and markets pharmaceutical drugs and devices for the treatment of hypoxic respiratory failure in newborns. It provides pharmaceutical products under the INOmax brand name. It was formerly known as INOCO, Inc. and changed its name to INO Therapeutics LLC in November 2003. The company was founded in 1998 and is based in Clinton, New Jersey. As of March 27, 2007, INO Therapeutics LLC operates as a subsidiary of Ikaria, Inc.

6 Route 173 West

Clinton, NJ 08809

United States

Founded in 1998

Phone:

908-238-6600

Fax:

908-238-6633

Key Executives for INO Therapeutics LLC

INO Therapeutics LLC does not have any Key Executives recorded.

INO Therapeutics LLC Key Developments

INO Therapeutics and Lee's Pharmaceutical (HK) Limited Sign Strategic Partnership for the Registration and Commercialization of Ikaria's INOMAX(R) Total Care Package Throughout the People's Republic of China

Ikaria Inc. through its INO Therapeutics subsidiary and Lee's Pharmaceutical (HK) Limited announced the signing of a strategic partnership for the registration and commercialization of Ikaria's INOMAX(R) Total Care package throughout the People's Republic of China, Hong Kong, Macau and Taiwan. Financial terms of the partnership were not disclosed. INOMAX(R) (inhaled nitric oxide) is the only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypoxic respiratory failure (HRF) associated with pulmonary hypertension in term and near-term infants greater than 34 weeks gestational age. HRF is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood. INOMAX(R) is a vasodilator which selectively relaxes pulmonary blood vessels and, in conjunction with ventilatory support and other appropriate agents, improves oxygenation in this fragile newborn population. INOMAX(R) Total Care is Ikaria's all inclusive offering of the INOMAX(R) drug, along with a drug-delivery system, training, and 24/7 technical assistance and support. In addition to the United States, INOMAX(R) has been approved and is currently commercialized by Ikaria and its partners in Australia, Canada, Europe, Japan, South Korea and select countries in South America.

Similar Private Companies By Industry

Company Name Region
Teva Biopharmaceuticals USA, Inc. United States
Hanall Pharmaceutical International, Inc. United States
NanoMedex Pharmaceuticals, Inc. United States
Cody Laboratories, Inc. United States
Pharmaceutics International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INO Therapeutics LLC, please visit www.inomax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.